| Variables | Anti-HDV antibodies | ||
| Positif (n = 53) | Négatif (n = 325) | p | |
| % male | 46 (86.8%) | 244 (75.1%) | ns |
| Mean age ± standard deviation | 41.1 ± 9.3 | 35.6 ± 11.7 | ns |
| Biochemical activity (n = 259) | 14 (41.2%) | 57 (25.3%) | 0.06 |
| Mean ALT | 46.5 ± 39 | 42.8 ± 118 | 0.06 |
| Mean GGT | 65 ± 71 | 40 ± 48 | 0.03 |
| HBeAg positive (n = 278) | 4 (12.9%) | 11 (4.5%) | ns |
| Anti HBe positive (n = 371) | 44 (91.7%) | 310 (96%) | ns |
| HBV DNA < 0 (n = 280) | 7 | 29 | ns |
| HBV DNA ≥2000 IU/ml | 13 28.3% | 72 30.8% | ns |
| Mean Log HBV DNA | 6.74 ± 3.3 | 7.58 ± 3.7 | ns |
| Histological activity (n = 153) |
|
|
|
| F ≥ 2 | 16 | 48 |
|
| A ≥ 2 | 7 | 14 |
|
| A or F ≥ 2 | 17 (65.4%) | 50 (39.4%) | 0.018 |
| METAVIR score |
|
|
|
| Fibrosis stage (n = 153) |
|
| 0.024 |
| 0 | 7 (26.9%) | 45 (35.4%) |
|
| 1 | 3 (11.5%) | 34 (26.8%) |
|
| 2 | 4 (15.4%) | 26 (20.5%) |
|
| 3 | 5 (19.2%) | 11 (8.7%) |
|
| 4 | 7 (26.9%) | 11 (8.7%) |
|
| Activity stage |
|
| 0.026 |
| 0 | 12 (48%) | 96 (77.4%) |
|
| 1 | 6 (24%) | 14 (11.3%) |
|
| 2 | 3 (12%) | 7 (5.6%) |
|
| 3 | 4 (16%) | 7 (5.6%) |
|